SBP GROUP (01177): Lixin Pharma Presents Preliminary Clinical Data for MK-2010/LM-299 at AACR 2026

Stock News04-19 18:12

SBP GROUP (01177) has announced that its wholly-owned subsidiary, Lixin Pharmaceutical Technology (Shanghai) Co., Ltd. ("Lixin Pharma"), has released initial clinical data for its self-developed innovative drug MK-2010/LM-299, a PD-1/VEGF bispecific antibody, at the 2026 American Association for Cancer Research (AACR) Annual Meeting. In November 2024, Lixin Pharma entered into a global exclusive licensing agreement with Merck & Co., known as MSD outside the United States and Canada, granting MSD exclusive rights to develop, produce, and commercialize LM-299 worldwide. MK-2010/LM-299 is an investigational tetravalent bispecific antibody that simultaneously targets programmed cell death protein-1 (PD-1) and vascular endothelial growth factor (VEGF). It utilizes an IgG-VHH fusion structure with Fcγ silencing functionality. Therapeutic strategies combining PD-1 inhibition with VEGF blockade, whether through co-administration or bispecific antibodies, have demonstrated clinical efficacy in various advanced solid tumors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1195027752?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-19 18:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195027752","market":"us","top_or_hot":-1,"title":"SBP GROUP (01177): Lixin Pharma Presents Preliminary Clinical Data for MK-2010/LM-299 at AACR 2026","media":"Stock News","content":"<p>SBP GROUP (01177) has announced that its wholly-owned subsidiary, Lixin Pharmaceutical Technology (Shanghai) Co., Ltd. (\"Lixin Pharma\"), has released initial clinical data for its self-developed innovative drug MK-2010/LM-299, a PD-1/VEGF bispecific antibody, at the 2026 American Association for Cancer Research (AACR) Annual Meeting. In November 2024, Lixin Pharma entered into a global exclusive licensing agreement with Merck & Co., known as MSD outside the United States and Canada, granting MSD exclusive rights to develop, produce, and commercialize LM-299 worldwide. MK-2010/LM-299 is an investigational tetravalent bispecific antibody that simultaneously targets programmed cell death protein-1 (PD-1) and vascular endothelial growth factor (VEGF). It utilizes an IgG-VHH fusion structure with Fcγ silencing functionality. Therapeutic strategies combining PD-1 inhibition with VEGF blockade, whether through co-administration or bispecific antibodies, have demonstrated clinical efficacy in various advanced solid tumors.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SBP GROUP (01177): Lixin Pharma Presents Preliminary Clinical Data for MK-2010/LM-299 at AACR 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSBP GROUP (01177): Lixin Pharma Presents Preliminary Clinical Data for MK-2010/LM-299 at AACR 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-19 18:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SBP GROUP (01177) has announced that its wholly-owned subsidiary, Lixin Pharmaceutical Technology (Shanghai) Co., Ltd. (\"Lixin Pharma\"), has released initial clinical data for its self-developed innovative drug MK-2010/LM-299, a PD-1/VEGF bispecific antibody, at the 2026 American Association for Cancer Research (AACR) Annual Meeting. In November 2024, Lixin Pharma entered into a global exclusive licensing agreement with Merck & Co., known as MSD outside the United States and Canada, granting MSD exclusive rights to develop, produce, and commercialize LM-299 worldwide. MK-2010/LM-299 is an investigational tetravalent bispecific antibody that simultaneously targets programmed cell death protein-1 (PD-1) and vascular endothelial growth factor (VEGF). It utilizes an IgG-VHH fusion structure with Fcγ silencing functionality. Therapeutic strategies combining PD-1 inhibition with VEGF blockade, whether through co-administration or bispecific antibodies, have demonstrated clinical efficacy in various advanced solid tumors.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1195027752","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195027752","pubTimestamp":1776593538,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SBP GROUP (01177) has announced that its wholly-owned subsidiary, Lixin Pharmaceutical Technology (Shanghai) Co., Ltd. (\"Lixin Pharma\"), has released initial clinical data for its self-developed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","BK1161":"生物科技","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","09939":"开拓药业-B","BK1574":"生物医药B类股","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","01177":"中国生物制药","BK1589":"北水核心资产","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","BK1515":"抗疫概念","BK1521":"挪威政府全球养老基金持仓","BK1191":"制药"},"translate_title":"SBP集团(01177)：立新制药在AACR 2026上展示MK-2010/LM-299的初步临床数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"09939":1,"01177":1},"content_text":"SBP GROUP (01177) has announced that its wholly-owned subsidiary, Lixin Pharmaceutical Technology (Shanghai) Co., Ltd. (\"Lixin Pharma\"), has released initial clinical data for its self-developed innovative drug MK-2010/LM-299, a PD-1/VEGF bispecific antibody, at the 2026 American Association for Cancer Research (AACR) Annual Meeting. In November 2024, Lixin Pharma entered into a global exclusive licensing agreement with Merck & Co., known as MSD outside the United States and Canada, granting MSD exclusive rights to develop, produce, and commercialize LM-299 worldwide. MK-2010/LM-299 is an investigational tetravalent bispecific antibody that simultaneously targets programmed cell death protein-1 (PD-1) and vascular endothelial growth factor (VEGF). It utilizes an IgG-VHH fusion structure with Fcγ silencing functionality. Therapeutic strategies combining PD-1 inhibition with VEGF blockade, whether through co-administration or bispecific antibodies, have demonstrated clinical efficacy in various advanced solid tumors.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1195027752","isCrawlerRequest":true}